Efficacy of Third-Line Therapy Using Bevacizumab in a Patient with Metastatic Colorectal Cancer

J. Gaulin; R. Kotb; E. Turcotte; G. Berard; B. Sawan; G. Schmutz; P. Beauregard

doi:10.3747/co.v16i5.395

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Case Report

1 September 2009

Efficacy of Third-Line Therapy Using Bevacizumab in a Patient with Metastatic Colorectal Cancer

and

Departments of Hematology and Oncology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada

Division of Hematology, Sherbrooke University, 3001–12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada

Departments of Nuclear Medicine, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada

⁴

Departments of Clinical Pharmacy, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada

Curr. Oncol.2009, 16(5), 84-86;https://doi.org/10.3747/co.v16i5.395

Version Notes

Order Reprints

Abstract

Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil–based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to folfiri and folfox chemotherapy regimens who showed a dramatic and durable response to bevacizumab and folfiri. We also review and discuss the available literature.

Keywords:

colorectal cancer; bevacizumab; third-line therapy

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Response to 5-Fluorouracil in Metastatic Extramammary Paget Disease of the Scrotum Presenting as Pancytopenia and Back Pain

Resolution of Severe Oncogenic Hypophosphatemic Osteomalacia after Resection of a Deeply Located Soft-Tissue Tumour